Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

High Throughput Pre-Clinical Models to Determine a Synergistic Molar Ratio of 5-Azacitidine to Venetoclax and Uncover Resistance Mechanisms to 5-Azacitidine and Venetoclax Combination Therapy in Acute Myeloid Leukemia

Mithun Milind Sarangdhar, Eric O'Brien, Brett VanCauwenbergh, Jackson Alexander, Caroline Theile, Mitali Basu, Mayur Sarangdhar, William Seibel, John P Perentesis

Blood (2022) 140 (Supplement 1): 10693–10694.

https://doi.org/10.1182/blood-2022-163770

Published: 2022

Journal Articles

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Sydney Fobare, Shelley Orwick, Jessica Kohlschmidt, Tom Sesterhenn, Krzysztof Mrózek, Ben Wronowski, Megan Johnstone, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, John P Perentesis, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd

Blood (2022) 140 (Supplement 1): 743–744.

https://doi.org/10.1182/blood-2022-160323

Published: 2022

Journal Articles

Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement

Mark Wunderlich, MS, Jing Chen, Eric O'Brien, BSc, Nicole Manning, Christina Sexton, Luke Byerly, John P Perentesis, Benjamin Mizukawa, James C Mulloy

Blood (2019) 134 (Supplement_1): 3766.

https://doi.org/10.1182/blood-2019-129225

Published: 2019

Journal Articles

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Laura Agresta, MD, Maureen M O'Brien, MD, Kana Mizuno, PhD, Robin Norris, MD MS, MPH, Erin H. Breese, MD PhD, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, Lynn Lee, MD, Adam Lane, PhD, Robert B. Lorsbach, MD PhD, Thomas D. Ryan, MD PhD, Pankaj B. Desai, PhD, Alexander A. Vinks, PharmD, PhD, H. Leighton Grimes, PhD, John P Perentesis, Michael J. Absalon, MD PhD

Blood (2019) 134 (Supplement_1): 3830.

https://doi.org/10.1182/blood-2019-121514

Published: 2019

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

Modeling Effective AML Therapies - Comparative Anti-Leukemic Synergy of BCL2 and MCL1 Inhibition Combined and with Chemotherapy

Eric O'Brien, BSc, Brett VanCauwenbergh, BSc, Jackson Alexander, Mitali Basu, MSc, Mark Wunderlich, MS, Mayur Sarangdhar, PhD, Benjamin Mizukawa, John P Perentesis

Blood (2019) 134 (Supplement_1): 3370.

https://doi.org/10.1182/blood-2019-131613

Published: 2019

Journal Articles

Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival

Kyung Hee Chang, Abel Sanchez-Aguilera, Shuhong Shen, Amitava Sengupta, Malav N. Madhu, Ashley M. Ficker, Susan K. Dunn, Ashley M. Kuenzi, Jorden L. Arnett, Rebecca A. Santho, Xabier Agirre, John P. Perentesis, Michael W. Deininger, Yi Zheng, Xose R. Bustelo, David A. Williams, Jose A. Cancelas

Blood (2012) 120 (4): 800–811.

https://doi.org/10.1182/blood-2011-06-361709

Published: 2012

Includes: Supplemental data

Journal Articles

Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.

Christine L Phillips, MD, Stella M. Davies, MBBS, PhD, Richard McMasters, MD, Maureen O'Brien, MD, MS, Michael J. Absalon, MD, PhD, Jeffrey A. Moscow, MD, Teresa Smolarek, PhD, John P. Perentesis, MD

Blood (2010) 116 (21): 1070.

https://doi.org/10.1182/blood.V116.21.1070.1070

Published: 2010

Journal Articles

Polymorphisms in the MGMT Gene as Predictors of Leukemia Risk and Response to Therapy in Children with AML.

Alex George, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Soheil Meshinchi, MD, Julie A. Ross, PhD, John P. Perentesis, MD, Stella M. Davies, MD PhD

Blood (2007) 110 (11): 1444.

https://doi.org/10.1182/blood.V110.11.1444.1444

Published: 2007

Journal Articles

Pharmacogenetic Predictors of Toxicity in Dose-Intensive Therapy for Pediatric Advanced-Stage Hodgkin’s Lymphoma.

John P. Perentesis, MD, Doojduen Villaluna, MS, Stella M. Davies, MBBS, PhD, Xiaowen Zhai, MD, PhD, Gretchen A. Radloff, MS, Michael A. Weiner, MD, Richard Sposto, PhD, Kara M. Kelly, MD

Blood (2006) 108 (11): 100.

https://doi.org/10.1182/blood.V108.11.100.100

Published: 2006

Journal Articles

Cytidine Deaminase Genotype Modifies the Toxicity of Therapy for Childhood AML.

Deepika Bhatla, MD, Robert B. Gerbing, MS, Heather D. Conner, BS, Todd A. Alonzo, PhD, Xiaowen Zhai, MD, Parinda Mehta, MD, Julie A. Ross, PhD, Hartmut Geiger, PhD, Beverly J. Lange, MD, John P. Perentesis, MD, Stella M. Davies, MBBS, PhD

Blood (2006) 108 (11): 17.

https://doi.org/10.1182/blood.V108.11.17.17

Published: 2006

Journal Articles

Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.

Mukta Sharma, MD, Todd A. Alonzo, PhD, April Sorrell, MD, Robert B. Gerbing, MA, Joanne M. Hilden, MD, Robert J. Arceci, MD, PhD, Gita Massey, MD, John J. Doyle, MD, Lisa Bayer, CPNP, John P. Perentesis, MD, Julie Ross, PhD, Franklin O. Smith, MD, Russell Brynes, MD, Jerry Hussong, MD, Lois Hathaway, Alan Gamis, MD

Blood (2006) 108 (11): 376.

https://doi.org/10.1182/blood.V108.11.376.376

Published: 2006

Journal Articles

XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report

Parinda A. Mehta, Todd A. Alonzo, Robert B. Gerbing, James S. Elliott, Tiffany A. Wilke, Rebekah J. Kennedy, Julie A. Ross, John P. Perentesis, Beverly J. Lange, Stella M. Davies

Blood (2006) 107 (1): 39–45.

https://doi.org/10.1182/blood-2005-06-2305

Published: 2006

Journal Articles

FAS Promoter Polymorphism and Etiology and Outcome of Childhood Acute Myeloid Leukemia.

Parinda A. Mehta, Todd A. Alonzo, James S. Elliot, Robert B. Gerbing, Tiffany A. Wilke, John P. Perentesis, Beverly J. Lange, Stella M. Davies

Blood (2004) 104 (11): 3011.

https://doi.org/10.1182/blood.V104.11.3011.3011

Published: 2004

Journal Articles

XPD Lys751Gln Polymorphism and Etiology and Outcome of Childhood Acute Myeloid Leukemia.

Parinda A. Mehta, Todd A. Alonzo, Robert B. Gerbing, John P. Perentesis, Beverly J. Lange, Stella M. Davies

Blood (2004) 104 (11): 3016.

https://doi.org/10.1182/blood.V104.11.3016.3016

Published: 2004

Journal Articles

Glutathione S- transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia

Stella M. Davies, Smita Bhatia, Julie A. Ross, William R. Kiffmeyer, Paul S. Gaynon, Gretchen A. Radloff, Leslie L. Robison, John P. Perentesis

Blood (2002) 100 (1): 67–71.

https://doi.org/10.1182/blood.V100.1.67

Published: 2002

NARROW

High Throughput Pre-Clinical Models to Determine a Synergistic Molar Ratio of 5-Azacitidine to Venetoclax and Uncover Resistance Mechanisms to 5-Azacitidine and Venetoclax Combination Therapy in Acute Myeloid Leukemia

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Modeling Effective AML Therapies - Comparative Anti-Leukemic Synergy of BCL2 and MCL1 Inhibition Combined and with Chemotherapy

Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival

Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.

Polymorphisms in the MGMT Gene as Predictors of Leukemia Risk and Response to Therapy in Children with AML.

Pharmacogenetic Predictors of Toxicity in Dose-Intensive Therapy for Pediatric Advanced-Stage Hodgkin’s Lymphoma.

Cytidine Deaminase Genotype Modifies the Toxicity of Therapy for Childhood AML.

Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.

XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report

FAS Promoter Polymorphism and Etiology and Outcome of Childhood Acute Myeloid Leukemia.

XPD Lys751Gln Polymorphism and Etiology and Outcome of Childhood Acute Myeloid Leukemia.

Glutathione S- transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only